AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, adding atopic dermatitis treatments to strengthen its dermatology portfolio. According to Bloomberg Intelligence analyst Sam Fazeli, the deal enhances AbbVie's presence in the dermatology segment.
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, adding treatments for atopic dermatitis to its dermatology portfolio. The transaction involves AbbVie and Apogee Therapeutics, a dermatology-focused company developing therapies for eczema and related inflammatory skin conditions. Bloomberg Intelligence analyst Sam Fazeli noted the deal enhances AbbVie's presence in the dermatology segment.
The $10.9 billion price tag represents a substantial commitment by AbbVie to expand beyond its core immunology franchise. The company has not disclosed the implied per-share price, premium to Apogee's trading levels, or the transaction's expected earnings impact. The acquisition brings Apogee's atopic dermatitis pipeline into AbbVie's commercial infrastructure, which already markets Skyrizi and Rinvoq for inflammatory conditions.
Continue reading
2 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.